Medovex Receives Regulatory Approval for DenerveX System in Australia
Medovex announced it obtained approval from the Australian Therapeutic Goods Administration for their DenerveX System.
Medovex (NASDAQ:MDVX) announced it obtained approval from the Australian Therapeutic Goods Administration (TGA) for their DenerveX System.
As quoted in the press release:
The approval comes ahead of schedule and the Company has also received its first order for the DenerveX System from Australia. On September 17, 2017, the Company expects to conduct sales and product training with its Australia distributor with anticipated initial procedures to be conducted shortly thereafter, following receipt of first shipments of the product.
Patrick Kullmann, Medovex President and COO, stated, “We’re clearly very pleased to have received regulatory approval ahead of schedule for the marketing and sale of our DenerveX Device in Australia. This paves the way for entry into a very important area globally, Asia Pacific. Australia is a highly regarded market by many in the global medical community for the quality of care and delivery of the latest technology for the treatment of chronic disease such as Facet Joint Pain.”